AI assistant
AbbVie Inc. — Director's Dealing 2023
Dec 22, 2023
29755_dirs_2023-12-22_8fcdc2e8-f178-4f12-9384-854e78574ed8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2023-12-14
Reporting Person: Thakkar Roopal (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.01 par value | 30225 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (Right to buy) | $93.50 | 2030-02-19 | Common Stock (18003) | Direct | |
| Option (Right to buy) | $105.92 | 2031-02-17 | Common Stock (7763) | Direct | |
| Option (Right to buy) | $144.54 | 2032-02-16 | Common Stock (7005) | Direct | |
| Option (Right to buy) | $149.62 | 2033-02-15 | Common Stock (8102) | Direct |
Footnotes
F1: Includes 6,918 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,001 shares on 02/20/2021, as to 6,001 shares on 02/20/2022, and as to 6,001 shares on 02/20/2023.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,588 shares on 02/18/2022 and as to 2,588 shares on 02/18/2023, and will become exercisable as to as to 2,587 shares on 02/18/2024.
F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,335 shares on 02/17/2023, and will become exercisable as to 2,335 shares on 02/17/2024 and as to 2,335 shares on 02/17/2025.
F5: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,701 shares on 02/16/2024, as to 2,701 shares on 02/16/2025 and as to 2,700 shares on 02/16/2026.